Pharmaceutical Coalition Challenges Medicare Over Unregulated Hemp Distribution
Washington, D.C., Friday, 5 June 2026.
A pharmaceutical coalition filed a federal appeal today, arguing strict FDA compliance penalizes businesses while Medicare freely distributes untested hemp products to seniors, severely skewing market fairness.
The Legal Battle Over Federal Compliance
On June 5, 2026, MMJ International Holdings, Smart Approaches to Marijuana (SAM), CIVEL, and a coalition of public health advocates formally lodged a Notice of Appeal with the U.S. Court of Appeals for the District of Columbia Circuit [1]. The coalition is challenging a lower federal district court’s decision to dismiss their lawsuit against the Centers for Medicare & Medicaid Services (CMS) Substance Access Beneficiary Engagement Incentive (BEI) program [1]. The initial dismissal was based on a lack of legal standing, as the court determined MMJ does not currently possess a commercial product on the Medicare market [1].
Medicare’s Hemp Distribution and Quality Concerns
The controversy fundamentally centers on the CMS BEI program, which was launched on April 1, 2026 [2]. This initiative permits Medicare providers to distribute hemp-derived cannabinoids to senior citizens under the ACO REACH and Enhancing Oncology Models [2]. The CMS program is slated to expand further into the LEAD model by January 2027 [2]. However, the coalition argues that this federal distribution channel favors products that have bypassed rigorous scientific scrutiny, effectively penalizing companies that comply with federal drug-development pathways [1].
The Broader Deregulation Push and DEA Rescheduling
This CMS dispute unfolds against a backdrop of sweeping, and highly contested, federal cannabis policy shifts driven by the executive branch. On April 28, 2026, the Trump administration issued a rescheduling directive (AG Order No. 6754-2026) designed to move state-licensed medical marijuana from Schedule I to Schedule III [2]. This triggered an immediate corporate gold rush, with multi-state operators racing to secure DEA registrations during an expedited application window that closes around June 27, 2026 [2]. Trulieve applied for over 200 dispensaries the day after the rule was published, followed by Verano in May, and Jushi Holdings on May 28, 2026 [2].
Future Market Restrictions and State-Level Complexities
Adding further complexity to the financial and regulatory outlook are impending federal caps on hemp derivatives. Beginning November 12, 2026, Congress will restrict hemp-derived cannabinoid products to a maximum of 0.4 milligrams of total THC per container [2]. This stringent limit is widely expected to disqualify a substantial portion of the existing commercial hemp market, fundamentally altering investment valuations and supply chains [2].